Dear Readers,
Welcome to this edition of CCA News. We are pleased to bring you highlights from the 12th Annual Cholangiocarcinoma Foundation Conference, held on April 11, 2025. This year’s event marked another significant step forward in our collective efforts to advance research, improve care, and foster community within the cholangiocarcinoma (CCA) landscape.
A key feature of the conference was the presentation of working-group summaries, each tackling essential aspects of CCA care and research. These multidisciplinary teams outlined progress and set new directions across 10 key domains. For instance, the Surgical Oncology group established a standardized framework to define resectability in CCA, paving the way for unified imaging and surgical trials. The Systemic Therapies group discussed the shift beyond gemcitabine-cisplatin-durvalumab, emphasizing biomarker-driven treatment combinations, and the Translational Research group called for enhanced use of organoids and multiomic models to better understand tumor biology, especially in metabolic dysfunction-associated steatotic liver disease–related cases.
In addition to scientific advances, the conference celebrated major milestones in research funding. Over $825,000 was awarded, including 11 fellowships of $75,000 each to early-career investigators. To date, the Foundation has awarded more than $3.83 million through 71 research fellowships since 2015. Finally, we were proud to recognize outstanding contributors to our community with the Mark R. Clements Awards: Christina Gambogi for Community Impact, Toni Pham for Volunteerism, and Dr Lewis Roberts for Vision, Innovation, and Collaboration.
Thank you for your continued support in advancing the mission of the Cholangiocarcinoma Foundation. Together, we are making meaningful strides in research, care, and hope.
Warm regards,
Milind M. Javle, MD
To sign up for our newsletter or print publications, please enter your contact information below.
